Furthermore, 16% (21/132) of the total cases were identified as a ‘PD-L1 high’ subset, which was characterized by more diffuse and/or especially strong PD-L1 expression and was associated with significantly higher numbers of tumor-associated CD3+ and CD8+ lymphocytes [55]. The gene discussed is CD8A; the disease is neoplasm.